about
Veterinary Medicine Needs New Green Antimicrobial DrugsBacterial Species-Specific Activity of a Fluoroquinolone against Two Closely Related Pasteurellaceae with Similar MICs: Differential In Vitro Inoculum Effects and In Vivo EfficaciesImpact of early versus later fluoroquinolone treatment on the clinical; microbiological and resistance outcomes in a mouse-lung model of Pasteurella multocida infectionImpact of Timing and Dosage of a Fluoroquinolone Treatment on the Microbiological, Pathological, and Clinical Outcomes of Calves Challenged with Mannheimia haemolytica.Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection modelIn vitro Degradation of Antimicrobials during Use of Broth Microdilution Method Can Increase the Measured Minimal Inhibitory and Minimal Bactericidal Concentrations.Species differences in pharmacokinetics and pharmacodynamics.Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal floraInfection-stage adjusted dose of beta-lactams for parsimonious and efficient antibiotic treatments: A Pasteurella multocida experimental pneumonia in mice.Comparison of the In vitro Activity of Five Antimicrobial Drugs against Staphylococcus pseudintermedius and Staphylococcus aureus Biofilms.Pharmacokinetic/pharmacodynamic assessment of the effects of parenteral administration of a fluoroquinolone on the intestinal microbiota: comparison of bactericidal activity at the gut versus the systemic level in a pig model.Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model.Comparison of the reduction in the antibacterial potency of a fluoroquinolone conferred by a single mutation in the quinolone resistance-determining region or by the inoculum size effect.En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach.Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Staphylococcus aureus Bacteria in a Hollow Fiber Infection Model.Comparison of in vitro static and dynamic assays to evaluate the efficacy of an antimicrobial drug combination against Staphylococcus aureusLevothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?
P50
Q26740600-6508BCCB-FAAD-46A0-8C5D-85BC8A1D0136Q35823020-ADD34D31-1964-4F8A-8DDA-C55E0C07AB95Q36401623-4597E37A-035D-433A-9136-9D3C9E119A0AQ36637193-EE8E4D06-E650-4DFF-8059-BCCAFD25755DQ37274635-2BE2F0BB-8833-4088-8395-2F30E132A821Q37523457-62B35801-2A87-4F2A-93D5-F0DA0A36749AQ37702887-60F1DE65-B211-4499-82E8-811853D8C273Q38324219-31FF0219-D2BE-4B39-929B-379071E6A638Q40106417-7ECE0017-EA02-46B1-9D14-4CEEDDA842AEQ40572997-DFC5B41E-3932-43BB-9226-87E12B0577A5Q42248243-8BD1019E-C700-4969-B5A2-CBD3FC635480Q42612081-51731CBE-4B68-4A46-BBD5-AF8C0496066DQ47422990-A880211C-C502-404D-89BD-1E9BBD3E9901Q49429759-52DCDA88-654E-4F3D-BAF2-299327F9C8EFQ52595189-F6690E67-95BA-4CC1-8B01-318F5B39ED1AQ61811302-ECBFC339-9CA4-4294-8FAE-381FE3F67ACBQ92866132-3B9C1242-737F-4F77-A7CF-70E591EAB01A
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Aude A Ferran
@ast
Aude A Ferran
@en
Aude A Ferran
@es
Aude A Ferran
@nl
Aude A Ferran
@sl
type
label
Aude A Ferran
@ast
Aude A Ferran
@en
Aude A Ferran
@es
Aude A Ferran
@nl
Aude A Ferran
@sl
prefLabel
Aude A Ferran
@ast
Aude A Ferran
@en
Aude A Ferran
@es
Aude A Ferran
@nl
Aude A Ferran
@sl
P106
P31
P496
0000-0002-6629-1088